Skip to site content

No Increased Risk of Prostate Cancer Found with the Use of Entacapone to Treat Parkinson's Disease

August 13, 2019

A clinical trail from March 2010 Exit Disclaimer: You Are Leaving  suggested a possible increased risk of prostate cancer with entacapone; however, after analysis of additional studies and evaluation of data from the Department of Veterans Affairs health care system, the FDA concludes that entacapone use is NOT associated with an increased risk of prostate cancer.

Entacapone is used to help manage Parkinson’s disease by increasing the amount of levodopa that is absorbed across the blood brain barrier. This helps to reduce the end-of-dose 'wearing-off' symptoms that occur when concentrations of levodopa drop below a therapeutic level.

The Safety Announcement can be found in its entirety by visiting the FDA’s website Exit Disclaimer: You Are Leaving .

Report adverse events involving this or other medicines to the MedWatch program as recommended in the Indian Health Manual and include “IHS” in the reporter section (section G).

Instructions for reporting can be found online at the NPTC Pharmacovigilance website.